EP4702023A1 - Inhibiteur de protéine contenant un domaine prolyl hydroxylase (phd) cristallin et leurs utilisations - Google Patents

Inhibiteur de protéine contenant un domaine prolyl hydroxylase (phd) cristallin et leurs utilisations

Info

Publication number
EP4702023A1
EP4702023A1 EP24796253.3A EP24796253A EP4702023A1 EP 4702023 A1 EP4702023 A1 EP 4702023A1 EP 24796253 A EP24796253 A EP 24796253A EP 4702023 A1 EP4702023 A1 EP 4702023A1
Authority
EP
European Patent Office
Prior art keywords
compound
xrpd
pattern
freebase
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24796253.3A
Other languages
German (de)
English (en)
Inventor
Yushu YIN
Jianyu Xu
Xing LIANG
Xiao DING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InSilico Medicine IP Ltd
Original Assignee
InSilico Medicine IP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InSilico Medicine IP Ltd filed Critical InSilico Medicine IP Ltd
Publication of EP4702023A1 publication Critical patent/EP4702023A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formes cristallines composé (1), d'un inhibiteur de protéine contenant un domaine de prolyl hydroxylase à petite molécule (PHD), ainsi que des compositions pharmaceutiques de ceux-ci, et des procédés d'utilisation de celles-ci dans le traitement de maladies ou d'états qui bénéficieraient d'un traitement avec un inhibiteur de protéine contenant un domaine de prolyl hydroxylase (PHD).
EP24796253.3A 2023-04-28 2024-04-26 Inhibiteur de protéine contenant un domaine prolyl hydroxylase (phd) cristallin et leurs utilisations Pending EP4702023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023091755 2023-04-28
PCT/CN2024/090097 WO2024222881A1 (fr) 2023-04-28 2024-04-26 Inhibiteur de protéine contenant un domaine prolyl hydroxylase (phd) cristallin et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4702023A1 true EP4702023A1 (fr) 2026-03-04

Family

ID=93255643

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24796253.3A Pending EP4702023A1 (fr) 2023-04-28 2024-04-26 Inhibiteur de protéine contenant un domaine prolyl hydroxylase (phd) cristallin et leurs utilisations

Country Status (5)

Country Link
EP (1) EP4702023A1 (fr)
KR (1) KR20250174914A (fr)
CN (1) CN121127469A (fr)
AU (1) AU2024260720A1 (fr)
WO (1) WO2024222881A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134660A1 (fr) * 2012-03-09 2013-09-12 Fibrogen, Inc. Composés 4-hydroxy-isoquinoléine comme inhibiteurs d'hydroxylase hif
WO2018218042A1 (fr) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Inhibiteurs de kinase de régulation de signal d'apoptose 1 et leurs procédés d'utilisation
TW201920108A (zh) * 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
KR20240095274A (ko) * 2021-10-28 2024-06-25 인실리코 메디신 아이피 리미티드 프롤릴 히드록실라제 도메인-함유 단백질 (phd) 억제제 및 그의 용도

Also Published As

Publication number Publication date
KR20250174914A (ko) 2025-12-15
AU2024260720A1 (en) 2025-10-30
WO2024222881A1 (fr) 2024-10-31
CN121127469A (zh) 2025-12-12

Similar Documents

Publication Publication Date Title
EP4339194A1 (fr) Sel d'addition d'acide d'un inhibiteur de rock, et forme cristalline, composition et utilisation pharmaceutique associée
US8343984B2 (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
CN116322678A (zh) Jak抑制剂的盐型、晶型及其制备方法和应用
JP2025148406A (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
TW202421139A (zh) 一種含氮雜環類化合物的可藥用鹽、晶型及製備方法
CN113045582A (zh) Parp-1/pi3k双靶点抑制剂或其药学上可接受的盐及其制备方法与用途
JP2026004551A (ja) イミダゾリノン誘導体の結晶形
US20250074908A1 (en) Salt of rock inhibitor, crystal form of salt, composition, and pharmaceutical use
CN117486874A (zh) 苯并杂芳环类化合物、其药物组合物及其应用
WO2024222881A1 (fr) Inhibiteur de protéine contenant un domaine prolyl hydroxylase (phd) cristallin et leurs utilisations
US20240116925A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
CN120917029A (zh) 结晶形式
WO2024222893A1 (fr) Inhibiteur de protéine (phd) contenant un domaine prolyl hydroxylase cristallin et ses utilisations
JP2026513705A (ja) 結晶性プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤及びその使用
WO2021073494A1 (fr) Sels d'un composé et leurs formes cristallines
WO2025167975A1 (fr) Inhibiteur cristallin de kinase dépendante de la cycline (cdk) 12 et/ou cdk13 et ses utilisations
WO2025209524A1 (fr) Inhibiteur de tead cristallin et ses utilisations
EP4660196A1 (fr) Forme cristalline de composé, son procédé de préparation et son utilisation
WO2023274310A1 (fr) Forme cristalline de dérivés de purine et leurs compositions pharmaceutiques
WO2026046267A1 (fr) Forme cristalline d'un dérivé de dihydrothiénopyrimidine et son utilisation
TW202444361A (zh) 雜環化合物的晶型、其鹽、其鹽的晶型及應用
WO2023174300A1 (fr) Forme cristalline d'un inhibiteur de btk, son sel acide de celui-ci, et forme cristalline du sel acide de celui-ci
TW202404610A (zh) 一種硼酸酯衍生物的結晶、其製備方法及用途
CN115232124A (zh) 一种atx抑制剂的结晶形式及其制备方法
BR112019024892B1 (pt) Inibidores da proteína quinase

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR